832 Results

People

  1. Pfister
    Pfister
  2. Lee
    Lee
  3. Sherman
    Sherman
  4. Riaz
    Riaz
  5. Dunn
    Dunn
  6. Wong
    Wong
  7. Ho
    Ho
  8. McBride
    McBride
  9. Shah
    Shah
  10. Tsai
    Tsai

Groups

  1. Head and Neck Service (832)
  2. Solid Tumor Oncology Division (832)
  3. Department of Medicine (826)
  4. Surgery (358)
  5. Radiation Oncology, Department of (310)
  6. Survivorship Research (310)
  7. Center for Pancreatic Cancer Research (173)
  8. Epidemiology and Biostatistics (162)
  9. Weinberg Fellows (161)
  10. Department of Pathology and Laboratory Medicine (155)
  1. "Head and Neck Service"
Formats
  1. Journal Article (407)
  2. Meeting Abstract (360)
  3. Book Section (20)
  4. Review (19)
  5. Editorial (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Correspondence (3)
  9. Book Whole (1)
  10. Conference Paper (1)
  11. Miscellaneous (1)
Groups
  1. Head and Neck Service (832)
  2. Solid Tumor Oncology Division (832)
  3. Department of Medicine (826)
  4. Surgery (358)
  5. Radiation Oncology, Department of (310)
  6. Survivorship Research (310)

More Groups

People
  1. David Pfister (389)
  2. Eric Sherman (339)
  3. Nancy Lee (266)
  4. Alan Ho (238)
  5. Nadeem Riaz (159)
  6. Lara Dunn (141)

More People

Years
  1. 2025 (12)
  2. 2024 (72)
  3. 2023 (55)
  4. 2022 (57)
  5. 2021 (58)
  6. 2020 (66)

More Years

Publications
  1. Journal of Clinical Oncology (205)
  2. International Journal of Radiation Oncology, Biology, Physics (140)
  3. Annals of Oncology (43)
  4. Cancer (33)
  5. Head & Neck (28)
  6. Journal of the National Comprehensive Cancer Network (28)

More Publications

Publishers
  1. American Society of Clinical Oncology (219)
  2. Elsevier Inc. (176)
  3. Wiley Blackwell (55)
  4. Oxford University Press (53)
  5. American Association for Cancer Research (46)
  6. Harborside Press (28)

More Publishers

Results (832)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
    Meeting Abstract

    Kang, H.; Ahn, M. J.; Keam, B.; Bowles, D. W.; Wong, D. J. L.; Ho, A. L.; Kim, S. B.; Worden, F. P.; Yun, T.; Jang, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
    Meeting Abstract

    Desilets, A.; Pfister, D. G.; Wong, W.; Sherman, E. J.; Fetten, J. V.; Hung, K. W.; Dunn, L.; Ho, A. L.; Michel, L. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J. M.; Zandberg, D. P.; Wong, D. J. L.; Yilmaz, E.; Sherman, E. J.; Hernando-Calvo, A.; Sacco, A. G.; Chung, C. H.; Bohr, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C. H.; Colevas, A. D. D.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Wong, W.; Cracchiolo, J. R.; Riaz, N.; Ganly, I.; Sherman, E. J.; Ho, A. L.; Morris, L.; Ghossein, R. A.; Haque, S.; Hung, K. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results
    Meeting Abstract

    Sherman, E. J.; De La Fuente, M. I.; Yaeger, R.; Tsai, F. Y.C.; Janku, F.; Butowski, N. A.; Allen, C. E.; Ammakkanavar, N. R.; Taylor, J. W.; Samara, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
    Meeting Abstract

    De La Fuente, M. I.; Rodon Ahnert, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Butowski, N. A.; Allen, C. E.; Ammakkanavar, N. R.; Taylor, . W.; Michelson, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • RET-altered cancers—A tumor-agnostic review of biology, diagnosis and targeted therapy activity
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Sherman, E. J.; Drilon, A.
    Cancers (2023)

    Fulltext@MSK | Save